Non-small cell lung cancer accounts for 75%of all lung tumours, and only about 10%of patients will remain alive 5 years after diagnosis. Few cytotoxic drugs currently registered produce more than a 15%response rate as a single agent or 30%-35%in combination, with only modest survival ...
Non-small cell lung cancerChemotherapyPhase II drugsDavid S. EttingerLung CancerEttinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991; 7: 113-22.Ettinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991;7: 113–122....
Non-small-cell lung cancer is the most common type of lung cancer. It's serious, but treatment can sometimes cure it or stop it from getting worse. WebMD explains.
Question:What are some of the updates in the non–small cell lung cancer treatment space? Melissa Johnson:It's been an exciting time for early-stage lung cancer. We've had 2 FDA approvals. In the last 6 months or so adjuvant atezolizumab, a PD-L1 inhibitor, and just rec...
Medically reviewed by Drugs.com. Last updated on Dec 2, 2024.Care notes Aftercare Ambulatory Discharge Inpatient Español Overview Risks Symptoms Diagnosis Treatment Management What is non-small cell lung cancer?Non-small cell lung cancer (NSCLC) is the most common type of lung cancer....
The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that cannot be treated with radiotherapy and in those with metastatic non-small-cell lung cancer and good performance status. This approach is also accepted in patients with earlier st...
The aim of this invited review is to evaluate the potential role of vinflunine for the treatment of non-small cell lung cancer (NSCLC). Areas covered: The potential role of vinflunine in NSCLC is discussed on the basis of the available data, including full papers and meeting abstracts. ...
Systemic treatment of advanced non-small cell lung cancer. Drugs Today (Barc) 2004; 40 :697-710Treatment of advanced non small cell lung cancer. Bareschino MA,Schettino C,Rossi A,et al. J Thorac Dis . 2011Hansen HH.Treatment of advanced non-small cell lung cancer.British Medical Journal....
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational r
Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (E... Takuya,Araki - 《Clinical Medicine Insights Oncology》 被引量:...